Several of the encephalitogenic peptides of MBP, PLP and MOG are also immunodominant in MS patients (4, 7, 9), and peptides of other myelin- (2’-3’ cyclic nucleotide phosphodiesterase (CNPase), myelin oligodendrocyte basic protein (MOBP), oligodendrocyte-specific protein (OSP), myelin-associated glycoprotein (MAG)) and non-myelin proteins (alpha-B crystallin, transaldolase H, S100 beta, contactin 2/TAG-1, RAS guanyl-releasing protein 2, RASGRP2, GDP L-fucose synthase, TSTA3, KIR4.1, anoctamin 2) have been described (5, 6, 10–12), but not yet studied to the same extent. This evidence concerns the gene ANO2 and myeloid sarcoma.